Masimo Corp MASI
We take great care to ensure that the data presented and summarized in this overview for MASIMO CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MASI
View all-
Black Rock Inc. New York, NY9.35MShares$1.58 Billion0.03% of portfolio
-
Politan Capital Management LP New York, NY4.71MShares$794 Million50.56% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.59MShares$773 Million0.01% of portfolio
-
Capital Research Global Investors Los Angeles, CA2.45MShares$414 Million0.09% of portfolio
-
Massachusetts Financial Services CO Boston, MA1.74MShares$292 Million0.1% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD1.66MShares$280 Million0.17% of portfolio
-
State Street Corp Boston, MA1.46MShares$247 Million0.01% of portfolio
-
Alliancebernstein L.P. New York, NY947KShares$160 Million0.06% of portfolio
-
Holocene Advisors, LP New York, NY836KShares$141 Million0.47% of portfolio
-
Geode Capital Management, LLC Boston, MA801KShares$135 Million0.01% of portfolio
Latest Institutional Activity in MASI
Top Purchases
Top Sells
About MASI
Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. It offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. It offers connectivity devices; and nasal high flow ventilation and neuromodulation solutions. It provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. The company was incorporated in 1989 and is headquartered in Irvine, California.
Insider Transactions at MASI
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 14
2025
|
Craig B Reynolds Director |
SELL
Open market or private sale
|
Direct |
2,053
-11.02%
|
$340,798
$166.13 P/Share
|
Mar 10
2025
|
Bilal Muhsin Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
30,000
-9.31%
|
$5,010,000
$167.64 P/Share
|
Mar 10
2025
|
Bilal Muhsin Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+35.64%
|
$1,110,000
$37.84 P/Share
|
Mar 01
2025
|
Bilal Muhsin Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,098
-25.09%
|
$1,522,424
$188.77 P/Share
|
Mar 01
2025
|
Bilal Muhsin Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+31.73%
|
-
|
Mar 01
2025
|
Blair Tripodi COO, Consumer Division |
SELL
Payment of exercise price or tax liability
|
Direct |
8,104
-54.03%
|
$1,523,552
$188.77 P/Share
|
Mar 01
2025
|
Blair Tripodi COO, Consumer Division |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
-
|
Mar 01
2025
|
Micah W Young EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,100
-31.72%
|
$1,522,800
$188.77 P/Share
|
Mar 01
2025
|
Micah W Young EVP & Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+37.0%
|
-
|
Feb 12
2025
|
Michelle Brennan Interim CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,816
-47.48%
|
$862,064
$179.51 P/Share
|
Feb 12
2025
|
Michelle Brennan Interim CEO |
BUY
Grant, award, or other acquisition
|
Direct |
8,916
+46.78%
|
-
|
Jan 15
2025
|
Robert A Chapek Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,665
+50.0%
|
-
|
Nov 13
2024
|
Tao Levy EVP, Bus Dev |
SELL
Payment of exercise price or tax liability
|
Direct |
14,398
-34.94%
|
$2,318,078
$161.68 P/Share
|
Nov 13
2024
|
Tao Levy EVP, Bus Dev |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+42.13%
|
-
|
Aug 08
2024
|
Joe E Kiani CEO and Chairman of the Board |
BUY
Exercise of conversion of derivative security
|
Direct |
231,748
+27.73%
|
$8,574,676
$37.84 P/Share
|
Jun 26
2024
|
Politan Capital Management LP |
BUY
Exercise of conversion of derivative security
|
Indirect |
1,228
+0.03%
|
-
|
Jun 26
2024
|
Michelle Brennan Interim CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,228
+50.0%
|
-
|
Jun 26
2024
|
Craig B Reynolds Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,228
+6.18%
|
-
|
May 01
2024
|
Craig B Reynolds Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+36.49%
|
$230,000
$23.04 P/Share
|
Apr 26
2024
|
Craig B Reynolds Director |
SELL
Open market or private sale
|
Direct |
40,000
-84.38%
|
$5,440,000
$136.17 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 392K shares |
---|---|
Grant, award, or other acquisition | 8.92K shares |
Payment of exercise price or tax liability | 43.5K shares |
---|---|
Open market or private sale | 72.1K shares |